Lv41
420 积分 2023-01-16 加入
Ivonescimab versus pembrolizumab for PD-L1-positive non-small cell lung cancer (HARMONi-2): a randomised, double-blind, phase 3 study in China
3天前
已完结
The Retrofit: Lessons From Sotorasib's Dosing Conundrum
3个月前
已完结
Getting the Dose Right in Drug Development for Rare Diseases: Barriers and Enablers
3个月前
已完结
Dosage Optimization: A Regulatory Perspective for Developing Oncology Drugs
3个月前
已完结
Advancing alternative methods to reduce animal testing
3个月前
已完结
Advances in Ovarian Cancer Care and Unmet Treatment Needs for Patients With Platinum Resistance: A Narrative Review
4个月前
已完结
Progress of antibody-drug conjugates (ADCs) targeting c-Met in cancer therapy; insights from clinical and preclinical studies
7个月前
已完结
Primate defensins
7个月前
已完结
Sensitive Skin Syndrome: An Update
7个月前
已完结
FGFR-targeted therapeutics: clinical activity, mechanisms of resistance and new directions
7个月前
已完结
皖公网安备34019202002308
